



Announcement Summary

Entity name

TELIX PHARMACEUTICALS LIMITED

Date of this announcement

Friday April 08, 2022

The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

ASX +security code	Security description	Total number of +securities to be issued/transferred	Issue date
New class - code to be confirmed	Share Appreciation Rights @ nominal \$4.95 each with an expiry date of 4 Apr 2027 (TLXO012)	2,690,291	05/04/2022
New class - code to be confirmed	Share Rights @ \$0.00 each with an expiry date of 4 Apr 2027 (TLXO013)	140,000	05/04/2022

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

TELEX PHARMACEUTICALS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1.2 Registered number type

ACN

Registration number

616620369

1.3 ASX issuer code

TLX

1.4 The announcement is

New announcement

1.5 Date of this announcement

8/4/2022



Part 2 - Issue details

2.1 The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

does not have an existing ASX security code ("new class")



Part 3C - number and type of +securities the subject of this notification (new class) where issue has not previously been notified to ASX in an Appendix 3B

ASX +security code

New class - code to be confirmed

+Security description

Share Appreciation Rights @ nominal \$4.95 each with an expiry date of 4 Apr 2027 (TLXO012)

+Security type

Other

ISIN code**Date the +securities the subject of this notification were issued**

5/4/2022

Will all the +securities issued in this class rank equally in all respects from their issue date? Yes**Were any of the +securities issued to +key management personnel (KMP) or an +associate?** Yes**Provide details of the KMP or +associates being issued +securities.**

Name of KMP	Name of registered holder	Number of +securities
Douglas Cubbin	Douglas Cubbin	48,251
Gabriel Liberatore	Gabriel Liberatore	49,115

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.

Pages 47 & 48 of the 2021 Annual Report detail the terms and performance measurements of Share Appreciation Rights (SARs) and other long-term incentives to be granted during 2022. https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02490832-3A588115?access_token=83ff96335c2d45a094df02a206a39ff4

Basis: SARs are issued in line with the Company's long-term incentive policy for key employees and new hires. The Company will satisfy the issue of shares from the exercise of SARs from the Employee Share Trust.

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Equity Incentive Plan approved at AGM held 12 May 2021. Notice of Meeting with summary of terms located here: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02362360-3A565079?access_token=83ff96335c2d45a094df02a206a39ff4

Any other information the entity wishes to provide about the +securities the subject of this notification

Grant date: 5 April 2022
Expiry date: 4 April 2027



Term: 5 years

Nominal Exercise price: \$4.95

Vesting: Subject to other conditions being met SARs will vest and become exercisable upon achievement of performance milestones.

- Tranche 1 (at target representing 50% of SARs issued) \hat{c} financial metric of Earnings Before Interest, Taxes and R&D expense (EBITRD) on a 3 year cumulative basis.
- Tranche 2 (at target representing 25% of SARs issued) \hat{c} value adding performance milestone of FDA or EMA marketing approval for TLX101-CDx (Glioblastoma diagnostic).
- Tranche 3 (at target representing 25% of SARs issued) \hat{c} value adding performance milestone of FDA or EMA marketing approval for TLX250-CDx (Renal cancer diagnostic).

At target, upon vesting and exercise 1 TLX share will be allocated for each 1 SAR exercised.

Number of SARs issued: 2,690,291

Code: TLX0012

Issue details

Number of +securities

2,690,291

ASX +security code

New class - code to be confirmed

+Security description

Share Rights @ \$0.00 each with an expiry date of 4 Apr 2027 (TLX0013)

+Security type

Other

ISIN code

Date the +securities the subject of this notification were issued

5/4/2022

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate?

No



Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.

Share Rights (Rights) @ \$0.00 each with an expiry date of 4 Apr 2027 (TLXO013)

Grant date: 5 April 2022

Expiry date: 4 April 2027

Term: 5 years

Exercise price per Right: \$0.00

Vesting: Subject to other conditions being met - including employee retention and individual performance - Rights will vest and become exercisable on 4 April 2025.

Number of Rights issued: 140,000

Code: TLXO013

Please provide a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Equity Incentive Plan approved at AGM held 12 May 2021. Notice of Meeting with summary of terms

located here: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02362360-3A565079?access_token=83ff96335c2d45a094df02a206a39ff4

Any other information the entity wishes to provide about the +securities the subject of this notification

Basis: Rights are issued to key employees in line with the Company's long-term incentive and retention policy. The Company will satisfy the issue of shares from the exercise of Rights from the Employee Share Trust.

Issue details

Number of +securities

140,000



Part 4 - +Securities on issue

Following the issue, conversion or payment up of the +securities the subject of this application, the +securities of the entity will comprise:
(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

4.1 Quoted +Securities (Total number of each +class of +securities quoted)

ASX +security code and description	Total number of +securities on issue
TLX : ORDINARY FULLY PAID	312,245,400

4.2 Unquoted +Securities (Total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
TLXAJ : OPTION EXPIRING 30-JUN-2024 EX \$1.83	1,300,000
TLXAI : OPTION EXPIRING 12-JAN-2024 EX \$2.23	3,300,000
TLXAE : OPTION EXPIRING 11-JUN-2022 EX 85C	800,400
TLXAG : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	3,445,000
TLXAH : OPTION EXPIRING 03-NOV-2023 EX \$2.30	1,310,000
TLXAM : OPTION EXPIRING 20-JUL-2026 EX \$5.37	1,017,992
TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL	225,000
TLXAL : OPTION EXPIRING 27-JAN-2026 EX \$4.38	1,900,058
New class - code to be confirmed : Share Appreciation Rights @ nominal \$4.95 each with an expiry date of 4 Apr 2027 (TLXO012)	2,690,291
New class - code to be confirmed : Share Rights @ \$0.00 each with an expiry date of 4 Apr 2027 (TLXO013)	140,000



Part 5 - Other Listing Rule requirements

5.1 Were the +securities issued under an exception in Listing Rule 7.2 and therefore the issue did not need any security holder approval under Listing Rule 7.1?

No

5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?

No

5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

Yes

5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

2,690,291

5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

No